AJP - Gastrointestinal and Liver Physiology, Vol 257, Issue 4 594-G600, Copyright © 1989 by American Physiological Society

ARTICLES

A new CCK analogue differentiates two functionally distinct CCK receptors in rat and mouse pancreatic acini

T. Matozaki, J. Martinez and J. A. Williams
Department of Physiology, University of Michigan, Ann Arbor 48109.

Analysis of the competitive inhibition of 125I-labeled cholecystokinin octapeptide (CCK-8) binding to isolated rat or mouse pancreatic acini showed that in both species CCK-8 interacts with two different affinity sites. A newly synthesized CCK analogue modified at the COOH-terminal phenylalanine residue totally inhibited 125I-CCK binding. This interaction occurred with sites of a single affinity in rat acini but with two different affinity sites in mouse acini. When acini were incubated with increasing concentrations of CCK-8, a biphasic stimulation of amylase release was observed. By use of rat acini, the analogs stimulated amylase release but caused no inhibition at supramaximal concentrations. By contrast, in mouse pancreatic acini, analogues showed a biphasic stimulation of amylase release similar to CCK-8. Both CCK-8 and the analogue stimulated [3H]leucine incorporation into protein at low concentrations in rat pancreatic acini. Higher concentrations of CCK-8 profoundly inhibited [3H]leucine incorporation, whereas the analogue had no inhibitory effect. Moreover, the analogue at higher concentrations blocked the inhibition of [3H]leucine incorporation caused by CCK-8 but did not affect carbamylcholine-induced inhibition. In mouse acini, however, the CCK analogue inhibited [3H]leucine incorporation similar to the effect of CCK-8. The results support the concept that occupancy of distinct affinity sites or states of the CCK receptor is associated with specific biological actions. A model of the CCK receptor is proposed in which two interchangeable affinity states exist. By occupying all the receptors in only one state, the new CCK analogues serve as partial agonists of some and antagonists of other actions of CCK.

This article has been cited by other articles:

				C. H. Kubisch and C. D. Logsdon Secretagogues differentially activate endoplasmic reticulum stress responses in pancreatic acinar cells Am J Physiol Gastrointest Liver Physiol, June 1, 2007; 292(6): G1804 - G1812. [Abstract] [Full Text] [PDF]

				M. D. Sans, M. J. DiMagno, L. G. D'Alecy, and J. A. Williams Caerulein-induced acute pancreatitis inhibits protein synthesis through effects on eIF2B and eIF4F Am J Physiol Gastrointest Liver Physiol, August 8, 2003; 285(3): G517 - G528. [Abstract] [Full Text] [PDF]

				T. O. Lankisch, Y. Tsunoda, Y. Lu, and C. Owyang Characterization of CCKA receptor affinity states and Ca2+ signal transduction in vagal nodose ganglia Am J Physiol Gastrointest Liver Physiol, June 1, 2002; 282(6): G1002 - G1008. [Abstract] [Full Text] [PDF]

				R. Poosti, L. di Malta, D. Gagne, N. Bernad, J.-C. Galleyrand, C. Escrieut, S. Silvente-Poirot, D. Fourmy, and J. Martinez The Third Intracellular Loop of the Rat and Mouse Cholecystokinin-A Receptors Is Responsible for Different Patterns of Gene Activation Mol. Pharmacol., April 13, 2001; 58(6): 1381 - 1388. [Abstract] [Full Text]

				B. Han and C. D. Logsdon CCK stimulates mob-1 expression and NF-kappa B activation via protein kinase C and intracellular Ca2+ Am J Physiol Cell Physiol, February 1, 2000; 278(2): C344 - C351. [Abstract] [Full Text] [PDF]

				E. Bignon, A. Bachy, R. Boigegrain, R. Brodin, M. Cottineau, D. Gully, J.-M. Herbert, P. Keane, C. Labie, J.-C. Molimard, et al. SR146131: A New Potent, Orally Active, and Selective Nonpeptide Cholecystokinin Subtype 1 Receptor Agonist. I: In Vitro Studies J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 742 - 751. [Abstract] [Full Text]

				I. Gukovsky, A. S. Gukovskaya, T. A. Blinman, V. Zaninovic, and S. J. Pandol Early NF-kappa B activation is associated with hormone-induced pancreatitis Am J Physiol Gastrointest Liver Physiol, December 1, 1998; 275(6): G1402 - G1414. [Abstract] [Full Text] [PDF]

				T. Akiyama, Y. Hirohata, Y. Okabayashi, I. Imoto, and M. Otsuki Supramaximal CCK and CCh concentrations abolish VIP potentiation by inhibiting adenylyl cyclase activity Am J Physiol Gastrointest Liver Physiol, November 1, 1998; 275(5): G1202 - G1208. [Abstract] [Full Text] [PDF]

				D. Ghanekar, E. M. Hadac, E. L. Holicky, and L. J. Miller Differences in Partial Agonist Action at Cholecystokinin Receptors of Mouse and Rat Are Dependent on Parameters Extrinsic to Receptor Structure: Molecular Cloning, Expression and Functional Characterization of the Mouse Type A Cholecystokinin Receptor J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1206 - 1212. [Abstract] [Full Text]

				B. Ji, A. S. Kopin, and C. D. Logsdon Species Differences between Rat and Mouse CCKA Receptors Determine the Divergent Acinar Cell Response to the Cholecystokinin Analog JMV-180 J. Biol. Chem., June 16, 2000; 275(25): 19115 - 19120. [Abstract] [Full Text] [PDF]

				M. D. Sans, S. R. Kimball, and J. A. Williams Effect of CCK and intracellular calcium to regulate eIF2B and protein synthesis in rat pancreatic acinar cells Am J Physiol Gastrointest Liver Physiol, February 1, 2002; 282(2): G267 - G276. [Abstract] [Full Text] [PDF]